News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

STRIDE regimen boosts OS in unresectable HCC
25 Feb 2022
byRoshini Claire Anthony
The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.
25 Feb 2022

Sarcoidosis patients at risk of haematologic, nonmelanoma skin cancers
25 Feb 2022
Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.
25 Feb 2022





